Your browser doesn't support javascript.
loading
Identification and validation of N-acetylputrescine in combination with non-canonical clinical features as a Parkinson's disease biomarker panel.
Peng, Kuan-Wei; Klotz, Allison; Guven, Arcan; Kapadnis, Unnati; Ravipaty, Shobha; Tolstikov, Vladimir; Vemulapalli, Vijetha; Rodrigues, Leonardo O; Li, Hongyan; Kellogg, Mark D; Kausar, Farah; Rees, Linda; Sarangarajan, Rangaprasad; Schüle, Birgitt; Langston, William; Narain, Paula; Narain, Niven R; Kiebish, Michael A.
Affiliation
  • Peng KW; BPGbio, 500 Old Connecticut Path, Framingham, MA, 01701, USA.
  • Klotz A; BPGbio, 500 Old Connecticut Path, Framingham, MA, 01701, USA.
  • Guven A; BPGbio, 500 Old Connecticut Path, Framingham, MA, 01701, USA.
  • Kapadnis U; BPGbio, 500 Old Connecticut Path, Framingham, MA, 01701, USA.
  • Ravipaty S; BPGbio, 500 Old Connecticut Path, Framingham, MA, 01701, USA.
  • Tolstikov V; BPGbio, 500 Old Connecticut Path, Framingham, MA, 01701, USA.
  • Vemulapalli V; BPGbio, 500 Old Connecticut Path, Framingham, MA, 01701, USA.
  • Rodrigues LO; BPGbio, 500 Old Connecticut Path, Framingham, MA, 01701, USA.
  • Li H; BPGbio, 500 Old Connecticut Path, Framingham, MA, 01701, USA.
  • Kellogg MD; BPGbio, 500 Old Connecticut Path, Framingham, MA, 01701, USA.
  • Kausar F; Department of Pathology, Harvard Medical School, Boston, MA, USA.
  • Rees L; Department of Laboratory Medicine, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA, 02115, USA.
  • Sarangarajan R; Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, 94158, USA.
  • Schüle B; Neurocrine Biosciences, San Diego, CA, 92130, USA.
  • Langston W; BPGbio, 500 Old Connecticut Path, Framingham, MA, 01701, USA.
  • Narain P; Department of Pathology, Stanford School of Medicine, Stanford, CA, 94305, USA.
  • Narain NR; Department of Pathology, Stanford School of Medicine, Stanford, CA, 94305, USA.
  • Kiebish MA; BPGbio, 500 Old Connecticut Path, Framingham, MA, 01701, USA.
Sci Rep ; 14(1): 10036, 2024 05 02.
Article in En | MEDLINE | ID: mdl-38693432
ABSTRACT
Parkinson's disease is a progressive neurodegenerative disorder in which loss of dopaminergic neurons in the substantia nigra results in a clinically heterogeneous group with variable motor and non-motor symptoms with a degree of misdiagnosis. Only 3-25% of sporadic Parkinson's patients present with genetic abnormalities that could represent a risk factor, thus environmental, metabolic, and other unknown causes contribute to the pathogenesis of Parkinson's disease, which highlights the critical need for biomarkers. In the present study, we prospectively collected and analyzed plasma samples from 194 Parkinson's disease patients and 197 age-matched non-diseased controls. N-acetyl putrescine (NAP) in combination with sense of smell (B-SIT), depression/anxiety (HADS), and acting out dreams (RBD1Q) clinical measurements demonstrated combined diagnostic utility. NAP was increased by 28% in Parkinsons disease patients and exhibited an AUC of 0.72 as well as an OR of 4.79. The clinical and NAP panel demonstrated an area under the curve, AUC = 0.9 and an OR of 20.4. The assessed diagnostic panel demonstrates combinatorial utility in diagnosing Parkinson's disease, allowing for an integrated interpretation of disease pathophysiology and highlighting the use of multi-tiered panels in neurological disease diagnosis.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Parkinson Disease / Biomarkers / Putrescine Limits: Aged / Female / Humans / Male / Middle aged Language: En Year: 2024 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Parkinson Disease / Biomarkers / Putrescine Limits: Aged / Female / Humans / Male / Middle aged Language: En Year: 2024 Type: Article